GIP and type 2 diabetes mellitus: Tirzepatide which acts as adual agonist on both gastric inhibitory polypeptide (GIP) and GLP-1 receptors hasshown significant improvement in glycemic control in patients with T2DM, whilealso lowering low-density lipoprotein (LDL) levels and improving blood pressure(BP) [20].